

Combining network-guided GWAS to discover susceptibility mechanisms for breast cancer

Héctor Climente-González^{1,2,3}, Christine Lonjou^{1,2,3}, Fabienne Lesueur^{1,2,3}, GENESIS study collaborators, Dominique Stoppa-Lyonnet^{4,5,6}, Nadine Andrieu^{1,2,3}, Chloé-Agathe Azencott^{3,1,2}

¹Institut Curie, PSL Research University, F-75005 Paris, France;

²INSERM, U900, F-75005 Paris, France;

³MINES ParisTech, PSL Research University, CBIO-Centre for Computational Biology, F-75006 Paris, France;

⁴Service de Génétique, Institut Curie, F-75005 Paris, France;

⁵INSERM, U830, F-75005 Paris, France;

⁶Université Paris Descartes;

Systems biology provides a comprehensive approach to biomarker discovery and biological hypothesis building. It does so by jointly considering the statistical association between gene variation and a phenotype, and the biological context of each gene, represented as a network. In this work, we study the utility of six network methods to discover new biomarkers for breast cancer susceptibility by searching subnetworks highly associated to this phenotype. We interrogate a familial breast cancer genome-wide association study (GWAS) focused on *BRCA1/2* negative French women. We perform an in-depth benchmarking of the methods with regards to size of the solution subnetwork, their utility as biomarkers, and the stability and the runtime of the methods. Interestingly, a combination of solution subnetworks provided a concise subnetwork of 93 genes, enriched in known breast cancer susceptibility genes (*BABAM1*, *BLM*, *CASP8*, *FGFR2*, and *TOX3*, Fisher’s exact test P-value = 7.8×10^{-5}) and more central than average. Additionally, it includes subnetworks of mechanisms related to cancer, like protein folding (*HSPA1A*, *HSPA1B*, and *HSPA1L*) or mitochondrial ribosomes (*MRPS30*, *MRPS31*, *MRPS18B*). We also observed a general dysregulation in the neighborhood of *COPS5*, a gene related to multiple hallmarks of cancer. By trading statistical stringency for biological meaningfulness, most network methods get more compelling results than standard SNP- and gene-level analyses, recovering causal subnetworks tightly related to cancer susceptibility.

1 Introduction

In human health, genome-wide association studies (GWAS) aim at quantifying how single-nucleotide polymorphisms (SNPs) predispose to complex diseases, like diabetes or some forms of cancer [11]. To that end, in a typical GWAS thousands of unrelated samples are genotyped: the cases, suffering the disease of interest, and the controls from the general population. Then, a per-SNP statistical association test is conducted (e.g. logistic regression). Those SNPs with a P-value lower than a conservative Bonferroni threshold are candidates to further studies in an independent cohort. Once the risk SNPs have been discovered, they can be used for risk assessment, and to deepen our understanding of the disease.

GWAS have successfully identified thousands of variants underlying many common diseases [10]. However, the experimental setting also presents intrinsic challenges. Some of them stem from the high-dimensionality of the problem, as every GWAS to date studies more variants than samples are genotyped. This limits the statistical power of the experiment, as only variants with large and moderate effects can be detected. And it is particularly problematic since the prevailing view is that most genetic architectures involve many

variants with small effects [45]. Additionally, to avoid false positives, a conservative multiple test correction is applied, typically Bonferroni. However, Bonferroni is known to be overly conservative when the statistical tests are correlated, as is the case in GWAS [46]. Another open issue is the interpretation of the results, as the functional consequences of most common variants are not well understood. On top of that, recent large-sampled studies suggest that most of the genome contributes to a degree to any complex trait, in accordance with the infinitesimal model [5]. The recently proposed omnigenic model [7] offers an explanation: genes are very functionally inter-related and influence each other’s behavior, which allows alterations in most genes to impact the “core” genes directly involved in a disease’s mechanism. Hence, a comprehensive statistical framework which includes the structure of biological data might address the aforementioned issues.

In this regard many authors turn to network biology to handle the complex interplay of biomolecules that lead to disease [21]. As its name suggests, network biology models biology as a network, where the biomolecules under study, often genes, are nodes, and between them are the edges that link them. These functional relationships come from evidence that the genes jointly contribute to a biological function; for instance, their expression is correlated, or their products establish a protein-protein interaction. Under this view, complex diseases are not the consequence of a single altered gene, but of the interaction of multiple interdependent molecules [4]. In fact, an examination of biological networks shows that disease genes have differential properties [4] [37]. This is particularly true for cancer driver genes, which tend to be key players in connecting different, densely-connected communities of genes. Additionally, as genes that contribute to a disease tend to participate in similar biological functions, guilt-by-association strategies have proved effective at identifying disease genes [24].

Network-based, biomarker discovery methods exploit the guilt-by-association strategy to identify disease genes on GWAS data [2]. In essence, each SNP has a measure of association with the disease, given by the experiment, and functionally biological relationships, given by a network built on prior knowledge. Then, the problem becomes finding a functionally-related set of genes that is highly associated with the disease. Different solutions have been proposed to this problem, often stemming from divergent different mathematical frameworks and considerations of what the optimal solution looks like. Some methods strongly constrain the problem to certain kinds of subnetworks. Such is the extreme case of LEAN [23], which focuses on star subnetworks, i.e. instances where both a gene and its direct interactors are associated with the disease. Other algorithms, like dmGWAS [25] and heinz [18], focus on interconnected genes with high association with the disease. However, they differ in their tolerance to the inclusion of lowly associated nodes, and the possible number of disconnected subnetworks in the solution. Lastly, other methods also consider the topology of the network, favoring solutions that are densely interconnected; such is the case of HotNet2 [26], SConES [3], and SigMod [30].

In this work, we analyze the effectiveness of these six methods to discover new biomarkers on GWAS data. We focus on the GENESIS dataset [44], a study of familial breast cancer conducted in the French population. After a classical GWAS approach, we use these network-based methods to recover additional breast cancer biomarkers. Lastly, we carry out a comparison of the solutions obtained by the different methods, and aggregate them to obtain a consensus network of predisposition to familial breast cancer.

2 Methods

2.1 GENESIS

The GENE Sisters (GENESIS) study was designed to investigate risk factors for familial breast cancer in the French population [44]. Index cases are patients with infiltrating mammary or ductal adenocarcinoma,

who had a sister with breast cancer, and who have been tested negative for *BRCA1* and *BRCA2* pathogenic variants. Controls are unaffected colleagues and/or friends of the cases, born around the year of birth of the corresponding case (± 3 years). We focused on the 2577 samples of European ancestry, of which 1279 are controls and 1298 are cases. The genotyping was performed using the iCOGS array, a custom Illumina array designed to study genetic susceptibility of hormone-related cancers [41]. It contains 211155 SNPs, including SNPs putatively associated with breast, ovarian, and prostate cancers, SNPs associated with survival after diagnosis, and SNPs associated to other cancer-related traits, as well as functional candidate variants in selected genes and pathways.

2.2 Preprocessing and quality control

We discarded SNPs with a minor allele frequency lower than 0.1%, those not in Hardy - Weinberg equilibrium in controls (P-value < 0.001), and those missing on more than 10% of the samples. A subset of 20 duplicated SNPs in *FGFR2* were also removed. In addition, we removed the samples with more than 10% missing genotypes. After control for relatedness, 17 additional samples were removed (6 for sample identity error, 6 false “friend/control” having family link with other samples, 3 “friend/control” having a high relatedness score). Lastly, based on study selection criteria, 11 other samples were removed (1 control having cancer, 4 index cases with no affected sister, 3 half-sisters, 1 sister with CLIS, 1 with *BRCA1/2* mutation detected in the family, 1 with molecular diagnosis not received). The final dataset included 1271 controls and 1280 cases, genotyped over 197083 SNPs.

We looked for population structure that could create confounding associations. A PCA revealed no visual differential population structure between cases and controls (Supplementary Figure 1). Independently, we did not find evidence of genomic inflation ($\lambda = 1.05$) either, further confirming the absence of confounding population structure.

2.3 High-score subnetwork search algorithms

2.3.1 SNP and gene association

To measure association between a genotype and the phenotype, we performed a per-SNP 1 d.f. χ^2 allelic test using PLINK v1.90 [14]. Then, we used VEGAS2v2 to compute the gene-level association score [33] from the SNP P-values. In order to map SNPs to genes we used their overlap on the genome: all SNPs located within the boundaries of a gene, ± 50 kb, were mapped to that gene. To compute the gene association we used the 10% of SNPs linked to the gene with lowest P-values. We used the 62193 genes described in GENCODE 31 [20], although only 54612 could be mapped to at least one SNP. Out of those, we focused exclusively on the 32767 that had a gene symbol. Out of the SNPs 197083 remaining after quality control, 164037 were mapped to at least one of these genes.

We use such mapping to compare the outputs of methods that produce SNP- to those that produce gene-lists, and vice versa. In the former case, we consider any gene that can be mapped to any of the selected SNPs as selected as well. In the latter, we consider all the SNPs that can be mapped to that gene as selected by the method.

2.3.2 Mathematical notation

In this article, we use undirected, vertex-weighted networks, or graphs, $G = (V, E, w)$. $V = \{v_1, \dots, v_n\}$ refers to the vertices, with weights $w : V \rightarrow \mathbb{R}$. Equivalently, $E \subseteq \{\{x, y\} | x, y \in V \wedge x \neq y\}$ refers to the edges. When referring to a subnetwork S, V_S is the set of nodes in S and E_S is the set of edges in S. A

special case of subgraphs are *connected* subgraphs, which occur when every node in the subgraph can be reached from any other node.

On top of a weight, nodes have other properties provided by the topology of the graph. In this article we focus on two: degree centrality, and betweenness centrality. The degree centrality, or degree, is the number of edges that a node has. The betweenness centrality, or betweenness, is the number of times a node participates in the shortest paths between two other nodes.

In addition, we use several matrices that describe different properties of a graph. The described matrices are square, and have as many rows and columns as nodes are in the network. The element (i, j) represents a selected relationship between v_i and v_j . The *adjacency matrix* W_G contains a 1 when the corresponding nodes are connected, and 0 otherwise; the diagonal is zero. The *degree matrix* D_G is a diagonal matrix which contains the degree of the different nodes. Lastly, the *Laplacian matrix* L_G is defined as $L_G = D_G - W_G$.

2.3.3 Methods used

Table 1: Summary of the differences between the studied algorithms.

Method	Field	Nodes	Exhaustive	Solution	Components	Input	Scoring	Reference
dmGWAS	GWAS	Genes	No	-	1	Summary	$-\log_{10}(P)$	[25]
heinz	Omics	Genes	Yes	-	1	Summary	BUM	[18]
HotNet2	Omics	Genes	Yes	Module	≥ 1	Summary	Local FDR	[26]
LEAN	Omics	Genes	Yes	Star	≥ 1	Summary	$-\log_{10}(P)$	[23]
SConES	GWAS	SNPs	Yes	Module	≥ 1	Genotypes	χ^2	[3]
SigMod	GWAS	Genes	Yes	Module	1	Summary	$-\log_{10}(P)$	[30]

Field: field in which the algorithm was developed.

Nodes: the type of network, either gene (protein-protein interaction network usually) or a SNP network.

Exhaustive: whether all the possible solutions given the selected hyperparameters are explored.

Solution: additional properties are enforced on the solution subnetwork, other than being dense in high scores and connected.

Components: number of connected subnetworks in the solution.

Input: genotype data or GWAS summary statistics.

Scoring: how SNP/gene P-values are transformed into node scores.

Reference: original publication featuring the algorithm.

Beyond the assumption that genes that contribute to the same function will be nearby in the protein-protein interaction network (PPIN), they might be topologically related to each other in diverse ways (densely interconnected modules, nodes around a hub, a path, etc.). That is not the only choice to make: how to score the nodes, whether the affected mechanisms form a single connected component or several, how to frame the problem in a computationally efficient fashion, what is the best network to use, etc. In consequence, multiple solutions have been proposed. In this article, we examine six of them: five that explore the PPIN, and one which explores SNP networks. We selected methods that were open source, had an implementation available, and an accessible documentation. Their main differences are summarized in Table 1.

dmGWAS dmGWAS searches the subgraph with the highest local density in low P-values [25]. To that end it searches candidate subnetwork solutions using a greedy, “seed and extend”, heuristic:

1. Select a seed node.

2. Compute Stouffer’s Z-score Z_m for the current subgraph S as

$$Z_m = \frac{\sum_{i \in S} z_i}{\sqrt{k}}$$

where k is the number of genes in the subgraph; z_i is the score of gene i , computed as $\phi^{-1}(1 - \text{P-value}_i)$; and ϕ^{-1} is the inverse normal distribution function.

3. Identify neighboring nodes i.e. nodes at distance $\leq d$. We set $d = 2$.
4. Add the neighboring nodes whose inclusion increases the Z_{m+1} more than $Z_m \times (1 + r)$. In our experiments, we set $r = 0.1$.
5. Repeat 2-4 until no increment $Z_m \times (1 + r)$ is possible.

Lastly, the module’s Z-score is normalized as

$$Z_N = \frac{Z_m - \text{mean}(Z_m(\pi))}{\text{SD}(Z_m(\pi))}$$

where $Z_m(\pi)$ represent a vector containing 100 000 random subsets of the same number of genes.

We used the implementation of dmGWAS in the dmGWAS 3.0 R package [47]. We used the function *simpleChoose* to select the solution subnetwork, which aggregates the top 1% modules into the solution subnetwork.

heinz The goal of heinz is to identify the highest-scored connected subgraph on the network [18]. The authors propose a transformation of the genes’ P-value into a score that is negative under no association with the phenotype, and positive value when there is. This transformation is achieved by modelling the distribution of P-values by a beta-uniform model (BUM) parameterized by the desired FDR. Thus formulated, the problem is NP-complete. To solve it efficiently it is re-casted as the Prize-Collecting Steiner Tree Problem (PCST), which seeks to select the connected subnetwork S that maximizes the *profit* $p(S)$:

$$p(S) = \sum_{v \in V_S} p(v) - \sum_{e \in E_S} c(e).$$

where $p(v) = w(v) - w'$ is the *profit* of adding a node, $c(e) = w'$ is the *cost* of adding an edge, and $w' = \min_{v \in V_G} w(v)$. All three are positive quantities. heinz implements the algorithm from Ljubić et al. [31], which in practice is often fast and optimal, neither is guaranteed. We used BioNet’s implementation of heinz, available on Bioconductor [6, 19].

HotNet2 HotNet2 was developed to find connected subgraphs of genes frequently mutated in cancer [26]. To that end, it considers both the local topology of the network and the scores of the nodes. The former is captured by an insulated heat diffusion process: at the beginning, the score of the node determines its initial heat; iteratively each node yields heat to its “colder” neighbors, and receives heat from its “hotter” neighbors, while retaining part of its own (hence, *insulated*). This process continues until equilibrium is

reached, and results in a similarity matrix F . F is used to compute the similarity matrix E that accounts also for similarities in node scores as

$$E = F \text{diag}(w(V)),$$

where $\text{diag}(w(V))$ is a diagonal matrix with the node scores in its diagonal. We scored the nodes as in Nakka et al. [34], assigning a score of 0 for the genes with low probability of being associated to the disease, and $-\log_{10}(\text{P-value})$ to those likely to be. In this dataset, the threshold separating both was a P-value of 0.125, which was obtained using a local FDR approach [42]. To obtain densely connected subnetworks, HotNet2 prunes E , only preserving edges such that $w(E) > \delta$. Lastly, HotNet2 evaluates the statistical significance of the subnetworks by comparing their size to the size of networks obtained by permuting the node scores. HotNet2 has two parameters: the restart probability β , and the threshold heat δ . Both parameters are set automatically by the algorithm, and are robust [26]. HotNet2 is implemented in Python [27].

LEAN LEAN searches disregulated “star” gene subnetworks, that is, subnetworks composed by one central node and all its interactors [23]. By imposing this restriction, LEAN is able to exhaustively test all such subnetworks (one per node). For a particular subnetwork of size m , the P-values corresponding to the involved nodes are ranked as $p_1 \leq \dots \leq p_m$. Then, k binomial tests are conducted, to compute the probability of having k out of m P-values lower or equal to p_k under the null hypothesis. The minimum of these k P-values is the score of the subnetwork. This score is transformed into a P-value through an empirical distribution obtained via a subsampling scheme, where sets of m genes are selected randomly, and their score computed. Lastly, P-values are corrected for multiple testing through a Benjamini-Hochberg correction. We used the implementation of LEAN from the LEANR R package [22].

SConES SConES searches the minimal, modular, and maximally associated subnetwork in a SNP graph [3]. Specifically, it solves the problem

$$\arg \max_{S \subseteq G} \underbrace{\sum_{v \in V_S} w(v)}_{\text{association}} + \lambda \underbrace{\sum_{v \in V_S} \sum_{u \notin V_S} L_{vu}}_{\text{connectivity}} - \underbrace{\eta |V_S|}_{\text{sparsity}} \quad (1)$$

where λ and η are hyperparameters that control the sparsity and the connectivity of the model. Given two hyperparameters, the aforementioned problem has a unique solution, that SConES finds using a graph min-cut procedure. We used the version on SConES implemented in the R package martini [15]. As in Azencott et al. [3], we selected λ and η by cross-validation, choosing the values that produce the most stable solution across folds. Note that the solution to the above problem can consist of several connected subnetworks which are disconnected from each other. In this case, the selected hyperparameters were $\eta = 3.51$, $\lambda = 210.29$ for SConES GS; $\eta = 3.51$, $\lambda = 97.61$ for SConES GM; and $\eta = 3.51$, $\lambda = 45.31$ for SConES GI.

SigMod SigMod aims at identifying the most densely connected gene subnetwork that is most strongly associated to the phenotype [30]. It addresses an optimization problem similar to that of SConES (Equation 1), but using the adjacency matrix rather than the Laplacian matrix (Section 2.3.2), to quantify solutions containing many edges.

$$\arg \max_{S \in G} \underbrace{\sum_{v \in V_S} w(v)}_{\text{association}} + \lambda \underbrace{\sum_{v \in V_S} \sum_{u \in V_S} W_{vu}}_{\text{connectivity}} - \underbrace{\eta |V_S|}_{\text{sparsity}}.$$

As SConES, this optimization problem can also be solved by a graph min-cut approach.

SigMod presents three important differences with SConES. First it is designed for gene-gene networks. Second, by replacing the adjacency by the Laplacian matrix, it favors subnetworks containing many edges. SConES, instead, penalizes connections between the selected and unselected nodes. Third, it returns a single connected subnetwork, which it achieves by exploring a grid of hyperparameters and processing their respective solutions. Specifically, for the range of $\lambda = \lambda_{\min}, \dots, \lambda_{\max}$ for the same η , it prioritizes the solution with the largest change in size from λ_n to λ_{n+1} . Such a large change implies that the network is strongly interconnected. This results in one candidate solution for each η , which are processed by removing any node not connected to any other. A score is assigned to each candidate solution by summing their node scores and normalizing by size. The candidate solution with the highest standardized score is the chosen solution. SigMod is implemented in an R package [29].

Consensus In addition, we built a consensus network by retaining the nodes that were selected by at least two of the six methods (using SConES GI for SConES).

2.3.4 Gene-gene network

Out of the six methods tested, five use a gene-gene interaction network (Section 2.3.3). Although their respective statistical frameworks are compatible with any type of network (protein interactions, gene co-expression, regulatory, etc.), for practical reasons we focused on a PPIN, as they are interpretable, well characterized, and most of the methods were designed to scale appropriately to it. We built our PPIN from both binary and co-complex interactions stored in the HINT database (release April 2019) [16]. Unless specified otherwise, we used only interactions coming from high-throughput experiments to avoid biasing the topology of the network by well-studied genes with more known interactions on average. Out of the 146 722 interactions from high-throughput experiments that HINT stores, we were able to map 142 541 to a pair of gene symbols. The scoring function for the nodes changed from method to method (Section 2.3.3).

Additionally, we compared the results of the aforementioned PPIN with those obtained on another PPIN built using interactions coming from both high-throughput and targeted studies. In that case, out of the 179 332 interactions in HINT, we mapped 173 797 to a pair of gene symbols.

2.3.5 SNP networks

SConES [3] is the only of the studied methods designed to handle SNP networks. As in gene networks, two SNPs are linked in a SNP network when there is evidence of shared functionality between two SNPs. The authors suggested three ways of building these networks: connecting the SNPs consecutive in the genomic sequence (“GS network”); interconnecting all the SNPs mapped to the same gene, on top of GS (“GM network”); and interconnecting all SNPs mapped to two genes for which a protein-protein interaction exists (“GI network”). We focused on the GI network, as it is the network that fits better the scope of this article. However, at different stages of this work we also used GS and GM. For the GM network, we used the mapping described in Section 2.3.1. For the GI network, we used the PPI as described in Section 2.3.4. For all three networks the node score used is the association of the individual SNPs with the phenotype; specifically, we used the 1 d.f. χ^2 .

2.4 Evaluation of methods

2.4.1 Classification accuracy of selected biomarkers

A desirable solution is one that is sparse, while offering a good predictive power on unseen samples. We evaluated the predicting power of the SNPs selected by the different methods through the performance of an L1-penalized logistic regression trained exclusively on those SNPs to predict the outcome (case/control). The L1 penalty helps to account for LD to reduce the number of SNPs included in the model (size of the active set), while improving the generalization of the classifier. The value of the regularization parameter, which controls both the magnitude and the sparsity of the coefficients, was set by cross-validation. To that end, we used the different network-methods on a random subset of 80% of the samples. On this same subset we trained our classifier exclusively on the SNPs selected by a particular method. When the method retrieved a list of genes (all of them except SConES), all the SNPs mapped to any of those genes were used. Then we evaluated performance of the classifier on the remaining 20% of the dataset. We repeated this procedure 5 times to estimate the average and the deviation of the different performance measures. The performance measures we used were: size of the solution, size of the active set, specificity, and sensitivity. The size of the active set provides an estimate of a plausible, more sparse solution with a comparable predictive power to the original solution.

Additionally, for each of the methods, we evaluated their stability and their runtime. The stability of an algorithm is its sensitivity to small changes of the input, and is measured using the Pearson’s correlation between different runs as suggested in [36]. To obtain a baseline, we also performed the procedure using all the SNPs.

2.4.2 Biological relevance of the genes

An alternative way to evaluate the results is comparing our results to an external dataset. For that purpose, we recovered a list of 153 genes associated to familial breast cancer from DisGeNET [38]. Across this article we refer to these genes as *breast cancer susceptibility genes*.

Additionally, we used the summary statistics from the Breast Cancer Association Consortium (BCAC) [32]. BCAC has conducted one of the largest efforts in GWAS, involving over 120 000 women of European ancestry. As opposed to GENESIS, samples were not selected based on family history, and hence the study is enriched in sporadic breast cancers. Another difference is that BCAC is a relatively heterogeneous study on a pan-European sample, while GENESIS is a homogeneous dataset focused on the French population. Despite these differences, there should be shared genetic architecture. On top of that, that overlap should become larger at the gene level. For that purpose, we computed the gene association as in Section 2.3.1. The iCOGS array was used for genotyping in BCAC [41], the same array as for GENESIS [44]. Although imputed data are available, we used exclusively the SNPs available on GENESIS after quality control to make the results comparable.

2.5 Code availability

This work required developing computational pipelines for several GWAS analyses, such physically mapping SNPs to genes, computing gene scores, and performing six different network analyses. For each of those processes, a streamlined, project-agnostic pipeline with a clear interface was created. They are compiled in the following GitHub repository: <https://github.com/hclimente/gwas-tools>. The code that applies these pipelines to the GENESIS project, as well as the code that reproduces all the analyses in this article are

available at <https://github.com/hclimente/genewa>. Although the GENESIS dataset is not publicly available, the published code should work on any other GWAS dataset. All the produced gene subnetworks were deposited on NDEx (<http://www.ndexbio.org>), under the UUID e9b0e22a-e9b0-11e9-bb65-0ac135e8bacf.

3 Results

3.1 A conventional GWAS confirms that *FGFR2* is strongly associated with familial breast cancer

We conducted association analyses in the GENESIS dataset at both the SNP and the gene levels (Section 2.3.1). Two genomic regions have a P-value lower than the Bonferroni threshold in chromosomes 10 and 16 (Supplementary Figure 2A). The former overlaps with gene *FGFR2*; the latter with *CASC16*, and it is located near the protein-coding gene *TOX3*. Variants in both *FGFR2* and *TOX3* were related to breast cancer susceptibility in other cohorts negative for *BRCA1/2* [40]. Only the peak in chromosome 10 replicated in the gene-level analysis, with *FGFR2* just above the threshold of significance (Supplementary Figure 2B). These results show an overlap in the genetic architecture of the disease between the studied French population sample and other populations, especially at the gene level. In addition, there are other SNPs whose P-values, although higher than the conventional threshold of significance, show a strong association with familial breast cancer. The most prominent of such regions are 3p24 and 8q24, both of which have been associated to breast cancer susceptibility in the past [9, 43]. We applied an L1-penalized logistic regression (Section 2.4.1), a machine learning algorithm that searches a small subset of SNPs which provide good classification accuracy. Unconstrained by considerations about statistical significance, it selected 100 SNPs, from all the aforementioned regions and others (Supplementary Figure 2C). Yet, it is unclear why those SNPs were selected, as emphasized by the low association of some of them, which further complicates the biological interpretation. In this regard, and in opposition to what would be predicted by the omnigenic model, the genes to which this SNPs map to (Section ??) are not interconnected in the HINT protein-protein interaction network (Section ??). This motivates exploring network methods which, by trading statistical significance for biological relevance, search susceptibility subnetworks. In fact, such methods provided comparable classification accuracies to L1-penalized logistic regression (Figure 3D), while providing more interpretable solutions.

3.2 Network methods successfully identify genes associated with breast cancer

We applied six network methods to the GENESIS dataset (Section 2.3.3). As none of the networks examined by LEAN was significant (adjusted P-value < 0.05), we obtained five solutions (Supplementary Figure 1, Supplementary Files 1 and 2): one for each of the remaining four gene-based methods (Section 2.3.4), and one for SConES GI (Section 2.3.5). The solutions are very heterogeneous (Table 2 and Supplementary table 1), making hard to draw joint conclusions. HotNet2 produced the largest solution subnetwork with 440 genes. SConES GI failed to recover genes in the PPIN, but it recovered one genomic region mapped to RNA gene *RNU6-420P*. All solution subnetworks except LEAN's are, on average, more strongly associated to breast cancer than the whole PPIN (median P-values \ll 0.46), despite containing genes with higher P-values (Supplementary Figure 1A). This exemplifies the trade-off between statistical significance and biological relevance. However, there are nuances between solutions: heinz strongly favored highly associated genes, while dmGWAS is less conservative (median gene P-values 0.0012 and 0.19, respectively); SConES tended to select whole LD-blocks; and HotNet2 and SigMod were less likely to select lowly associated genes.




Fig. 1: TODO.

Table 2: Summary statistics on the results of multiple network methods on the gene-gene interaction network. The first row contains the summary statistics on the whole network.

Network	# genes	# edges	Betweenness	\hat{P}_{gene}	$\rho_{\text{consensus}}$
HINT HT	13 619	142 541	16 706	0.46	0.066
Consensus	55	117	74 062	0.0051	1
dmGWAS	194	450	49 115	0.19	0.41
heinz	4	3	113 633	0.0012	0.21
HotNet2	440	374	7 739	0.048	0.31
LEAN	0	0	-	-	-
SConES GI	0 (1)	0	-	-	-
SigMod	142	249	92 603	0.0083	0.73

genes: number of genes selected out of those that are part of the PPIN; for SConES GI the total number of genes, including RNA genes, was added in parentheses.

Betweenness: mean betweenness of the selected genes in the PPIN.

\hat{P}_{gene} : median P-value of the selected genes.

$\rho_{\text{consensus}}$: Pearson’s correlation between the subnetwork and the consensus network.

The solution subnetworks present other desirable properties. First, four of the methods succeeded at recovering genes involved in the disease (Supplementary Figure 1D), as their subnetworks were enriched in breast cancer susceptibility genes (dmGWAS, heinz, HotNet2, and SigMod, Fisher’s exact test one-sided P-value < 0.03). We also compared the outcome of the network methods to the association tests conducted on the population of European ancestry from the Breast Cancer Association Consortium (BCAC) [32] (Supplementary Figure 1D). Encouragingly, every solution subnetwork is enriched in genes or SNPs that are Bonferroni-significant in BCAC. This confirms the capability of network methods to find the same signal as in more powered studies by leveraging on prior knowledge. Second, the genes in four solution subnetworks display on average a higher betweenness centrality than the rest of the genes, a difference that is significant in three solutions (dmGWAS, and SigMod, Wilcoxon rank-sum test P-value $< 1.4 \times 10^{-21}$). This agrees with the notion that disease genes are more central than other, non-essential genes [37]. We observe that this conclusion holds in this disease, as known breast cancer susceptibility genes have higher betweenness centrality than others (one-tailed Wilcoxon rank-sum test P-value $= 2.64 \times 10^{-5}$, Supplementary Figure 5C). Interestingly, SConES’ selected SNPs are also more central than the average SNP (Supplementary table 1), suggesting that causal SNPs are also more central than unrelated SNPs. However, very central nodes are also more likely to be connecting a random pair of nodes, making them more likely to be selected by the examined methods. Hence, further work is needed to draw conclusions.

As the solutions were quite different from each other it is hard to draw joint conclusions. The 4-gene solution selected by heinz includes the breast cancer susceptibility gene *TOX3*, in region 16q12. By dealing with SNP networks, SConES studies the association of non-coding regions, as well as SNPs in any gene, coding or not. In fact, SConES GI, which adds to GM the interactions between genes, retrieves 4 subnetworks in intergenic regions, and 1 overlapping an RNA gene (*RNU6-420P*). SigMod, despite being related to SConES, produces a vastly different, large solution. On top of recovering three breast cancer susceptibility genes, a keratin-based region of its subnetwork affects the cytoskeleton (*structural constituent of cytoskele-*

ton, GO enrichment’s adjusted P-value = 9.10×10^{-4}), a potentially novel susceptibility mechanism for cancer susceptibility. Interestingly, dmGWAS solution is also related to cytoskeleton (*tubulin binding*, GO enrichment’s adjusted P-value = 0.031). But, additionally, it includes a submodule of proteins related to *unfolded protein binding* (GO enrichment’s adjusted P-value = 0.045), which has been previously related to cancer susceptibility [13]. Lastly, HotNet2 produced 135 subnetworks, 115 of which have less than five genes. The second largest subnetwork (13 nodes), contains the two breast cancer susceptibility genes *CASP8* and *BLM*.

3.3 A case study: the consensus network




Fig. 2: Consensus subnetwork on GENESIS (Section 2.3.3). Each node is represented by a pie chart, which shows the methods that selected it. The labeled genes have a VEGAS2v2 P-value < 0.001 and/or are known breast cancer susceptibility genes (colored in pink).

The heterogeneity in the solutions suggested, and the shared encouraging properties suggested that each method was capturing different susceptibility mechanisms. Due to the limited overlap between methods, only 20 genes were common to more than two of them (Supplementary Figure 5A). Encouragingly, the more methods selected a gene, the higher its association was (Supplementary Figure 5B). To leverage on their strengths and compensate their respective weaknesses, we built a consensus subnetwork that captures the mechanisms most shared among the solution subnetworks (Section 2.3.3). This subnetwork (Figure 2) contains 93 genes and shares the aforementioned properties of the individual solutions: enrichment in breast cancer susceptibility genes (Fisher’s exact test P-value = 7.8×10^{-5}), higher betweenness centrality than the rest of the genes (Wilcoxon rank-sum test P-value = 4.29×10^{-18}) and TODO pathways. Topologically,

the consensus network can be divided into a large connected component composed of 49 genes, and multiple smaller subnetworks. Among the latter, 14 of the 93 genes are in subnetworks of size 1 (isolated) or 2, implying that they do not have a consistently altered neighborhood, but are strongly associated themselves (TODO TEST). Some of them are known breast cancer susceptibility gene like *FGFR2* (Section 3.1) and *SLC4A7* (VEGAS P-value = 2.70×10^{-5} , Ahmed et al. [1]).

TODO Yet, there are other novel functions: Globally, a GO enrichment shows the involvement of two cellular processes: unfolded protein binding, and structural constituent of cytoskeleton (adjusted P-values of 0.001, 0.001, respectively), which were already observed in different solutions (Section 3.2). Remarkably, many of the selected genes are related to mitochondrial translation. For instance, MRPS30 (VEGAS P-value = 0.001), encodes a mitochondrial ribosomal protein and was also linked to breast cancer susceptibility [39]. Albeit disconnected from MRPS30, the consensus network includes a 2-node subnetwork composed of two mitochondrial ribosomal protein (MRPS31 - VEGAS P-value = 7.67×10^{-3} - and MRPS18B - VEGAS P-value = 7.92×10^{-3}), which suggests an involvement of mitochondrial ribosomes in carcinogenesis [?].

We also examined the topological properties of the nodes. The genes in the consensus network have higher betweenness centrality than the rest of the genes (Wilcoxon rank-sum test P-value = 4.29×10^{-18}). Interestingly, within genes in the consensus network, cancer genes are as central as non-cancer genes (Wilcoxon rank-sum test P-value = 0.57). Centrality, however, is weakly anti-correlated with association to the disease (Pearson correlation coefficient = -0.26, Supplementary Figure 5D), which suggests that some highly central genes were selected because they were on the shortest path between two highly associated genes. In view of this, we hypothesize that highly central genes might contribute to the heritability through consistent alterations of their neighborhood, consistent with the omnigenic model of disease [7]. For instance, the most central node in the consensus network is *COPS5* (Supplementary Figure 4), a gene related to multiple hallmarks of cancer and which is overexpressed in multiple tumors, including breast and ovarian cancer [28]. Despite its lack of association in GENESIS (VEGAS P-value = 0.22), its neighbors in the consensus subnetwork have consistently low P-values (median VEGAS P-value = 0.006).

3.4 Methods are comparably stable, and produce similarly good predictors

We compared the six methods in a 5-fold subsampling setting (Section 2.4.1). Specifically, we measured five properties (Figure 3): size of the solution subnetwork; sensitivity and specificity of an L1-penalized logistic regression on the selected SNPs; stability; and computational runtime.

Both solution size and active set of SNPs selected by Lasso varies greatly between the different methods (Figure 3A). Heinz produced the smallest solutions, with an average of 182 selected SNPs. The largest solutions come from SConES GI (6 256.6 SNPs), and dmGWAS (4 255.0 SNPs). Interestingly, heinz has the highest proportion of the selected SNPs that go into the active set (99.9%), although it is high for all the methods (> 86%). This suggests these methods are selecting informative SNPs on average.

To determine whether the selected SNPs could be used for patient classification we computed the sensitivity and the specificity of the classifier on the testing data (Figure 3B). All classifiers' sensitivities were in the 0.42 – 0.51 range; the specificities, between 0.54 and 0.62. On average, SigMod had the highest sensitivity (0.51); dmGWAS, the highest specificity (0.52). Both heinz and SigMod had on average better sensitivity than the classifier trained on all the SNPs, but none had superior specificity. However, the differences are negligible, well within the 95% confidence interval.

Another desirable quality of an algorithm is stability of the solution with regards to different inputs (Section 2.4.1). Both heinz and LEAN displayed a high stability in our benchmark, consistently selecting the same genes and no genes over the 5 subsamples, respectively (Figure 3C). Conversely, the other methods displayed similarly low stabilities.




Fig. 3: Comparison of network-based GWAS methods on GENESIS. Each method was run 5 times of a random subset of the samples, and tested on the remaining samples (Section 2.4.1). **(A)** Number of SNPs selected by each method and number of SNPs on the active set used by the Lasso classifier. Points are the average over the 5 runs; lines represent the standard error of the mean. A grey diagonal line with slope 1 is added for comparison. For reference, the active set of Lasso using all the SNPs included, on average, 154 117.4 SNPs. **(B)** Sensitivity and specificity on test set of the L1-penalized logistic regression trained on the features selected by each of the methods. In addition, the performance of the classifier trained on all SNPs is displayed. Points are the average over the 5 runs; lines represent the standard error of the mean. **(C)** Pairwise Pearson's correlations of the solutions used by different methods. A Pearson's correlation of 1 means the two solutions are the same. A Pearson's correlation of 0 means that there is no SNP in common between the two solutions. **(D)** Runtime of the evaluated methods, by type of network used (gene or SNP). For gene network-based methods, inverted triangles represent the runtime of the algorithm itself, and circles the total time, which includes the algorithm themselves and the additional 119 980 seconds (1 day and 9.33 hours) which took VEGAS2v2 on average to compute the gene scores from SNP summary statistics.

In terms of computational runtime, the fastest method was heinz (Figure 3D), which leverages on its ability to find efficiently the solution in a few seconds, and HotNet2 was slowest (3 days and 14 hours on average). Including the time required to compute the gene scores slows down considerably gene-based methods; on this benchmark, that step took on average 1 day and 9.33 hours. Considering that, it took 5 days on average for HotNet2 to produce results.

3.5 The consensus overcomes the problems of the individual solutions




Fig. 4: Drawbacks confronted when using network guided methods. **(A)** dmGWAS solution subnetwork. Genes with a P-value < 0.1 are highlighted in red. **(B)** Centrality degree and $-\log_{10}$ of the VEGAS2v2 P-value for the nodes in SigMod solution subnetwork. **(C)** Genomic regions where either SConES GS, GM or GI select SNPs.

In practice, and despite their similarities and their involvement in cancer mechanisms, the solutions are remarkably different (Supplementary Figure 3A). That is due to the particularities of the methods which directly or indirectly provide information about the dataset. For instance, the fact that LEAN did not

provide any biomarkers implies that there is no gene such that both itself and its environment are on average strongly associated with the disease.

In this dataset, heinz’s solution is very conservative, providing a small solution with the lowest median P-value for the subnetwork (Table 2). Due to this parsimonious and highly associated solution, it was the best method to select a set of good biomarkers for classification. (Figure 3B). Its conservativeness stems from its preprocessing step, which models the gene P-values as a mixture model of a beta and a uniform distribution, controlled by an FDR parameter. Due to the limited signal at the gene level in this dataset (Figure 2B), only 36 of them are retain a positive score after applying the BUM model (Section 2.3.3). Hence, heinz’s solution subnetwork consists only of 4 genes, which does not provide much insight of the biology of cancer. Importantly, it ignores genes that are strongly associated to cancer in this dataset like *FGFR2*.

On the other end of the spectrum, we have large solutions provided by dmGWAS, HotNet2, and SigMod. dmGWAS’ subnetwork is the least associated subnetwork on average. This is due to the greedy framework it uses, which has a bias for larger solutions [35]. This framework considers all nodes at distance 2 of the examined, and accepts weakly associated genes if they are linked to another, strongly associated one. This is exacerbated when the results of successive greedy searches are aggregated, leading to a large, tightly connected cluster of unassociated genes (Figure 4A). SigMod displays the same tendency, as the most central genes are the least associated to the disease (Figure 4B). This relatively low signal-to-noise ratio combined with the large solution requires additional analyses to draw conclusions, such as enrichment analyses. In the same line, HotNet2’s subnetwork is even harder to interpret, being composed of 440 genes divided into 135 subnetworks. Lastly, SigMod misses some of the most strongly associated, breast cancer susceptibility genes in the dataset, like *FGFR2* and *TOX3*.

By virtue of using a SNP subnetwork, SConES analyzes each SNP in their context. It therefore selects SNPs in genes none of whose interactors are associated to the disease, as well as SNPs in non-coding regions or in non-interacting genes. In fact, due to linkage disequilibrium, such genes are favored by SConES, as selecting SNPs in an LD block which overlaps with a gene favors selecting the rest of the gene. This might explain why the GS and GM networks, heavily affected by linkage disequilibrium, produce similar results (Supplementary Figure 3B). On the other hand, SConES penalizes selecting SNPs and not their neighbors. This makes it conservative regarding SNPs with many interactions, for instance those mapped to hubs in the PPIN. For this reason, SConES GI did not select any protein coding gene, despite selecting similar regions as SConES GS (Figure 4C). In fact SConES GS and SConES GM select regions related to breast cancer, like 16q12 (*TOX3*, Section 3.1), 3p24 (*SLC4A7/NEK10* [1]), 5p12 (*FGF10, MRPS30* [39]), and 10q26 (*FGFR2*, Section 3.1). On top of that only SConES GS selects region 8q24 (*POU5F1B* [8]). We hypothesize that the lack of results on the PPIN network of SConES GI and LEAN are due to the same cause: the absence of joint association of a module. Although in the case of SConES other hyperparameters could lead to a more informative solution (e.g. lower λ , Section 2.3.3), it is unclear what is the best strategy to find them. In addition, due to the iCOGS SNP array design, the genome of GENESIS participants has not been unbiasedly surveyed: some regions are fine-mapped — which might distort gene structure in GM and GI networks — while others are under studied — hurting the accuracy with which the GS network captures the genome structure.

3.6 Network methods boost biomarker discovery

We compared the results of different network methods to the European cohort of BCAC, the largest GWAS to date in breast cancer (Section 2.4.2). This comparison is pertinent, since despite caveats we expect a significant shared genetic factors with GENESIS, and since it is a much larger study (XX times more

samples, 13 million SNPs through imputation). We conducted a study at both the SNP and the gene levels, equivalent to the one shown in Section 3.1 for GENESIS. Despite the low overlap using a conventional approach (TODO), the solutions provided by the different network approaches overlap significantly (Fisher’s exact test $P\text{-value} \leq X \times 10^{-X}$). This illustrates the ability of network guided GWAS to boost discovery.

4 Discussion

In this article we evaluate the viability of a systems biology take on genetic studies by examining a GWAS dataset on familial breast cancer. Such an approach addresses two of the largest issues with GWAS: interpretability and an overly conservative statistical framework that hinders discovery. This is achieved by considering the biological context of each of the genes and SNPs. Based on divergent considerations of what the desired set of biomarkers is, several methods for network-guided biomarker discovery have been proposed. We reviewed the performance of six of them on GWAS. Despite their differences, most of them produced a relevant subset of biomarkers, recovering known familial breast cancer genes. We also discuss the limitations of such analyses, related to the lack of known interactions around some genes. A crucial step for the gene based methods is the computation of the gene score. In this work we used VEGAS2v2 [33] due to the flexibility it offers to use user-specified gene annotations. However, it presents known problems (selection of an appropriate percentage of top SNPs, long runtimes and P-value precision limited to the number of permutations [34]), and other algorithms might have more statistical power.

The network methods we studied differ in what the optimal solution subnetwork looks like, which acted as a double-edged sword. In one end of the spectrum, SConES and heinz preferred small, highly associated solutions, providing a conveniently short list of biomarkers, at the expense of not shedding much light on the etiology of the disease. On the other end, SigMod and dmGWAS gravitate towards larger, less associated solutions which provide a wide overview of the biological context. While this deepens our understanding of the disease and provide biological hypotheses, they require further analyses, which risk oversimplifying their richness. HotNet2 balances both approaches at the expense of producing a constellation of many, highly associated, small subnetworks. Despite their differences, all the solutions produced comparable discrimination capabilities on a linear classifier trained on them. On the negative side, the methods were also remarkably unstable, and hence likely to produce very different solutions in face of slightly different inputs.

To overcome the problems posed by the individual methods while exploiting their strengths, we propose combining them into a consensus subnetwork. We use a straightforward aggregation to generate it, including any node that was recovered by at least two methods. The resulting network is a synthesis of the altered mechanism: it is smaller than the largest solutions (SigMod and dmGWAS), which makes it more manageable, and includes the majority of the strongly associated smaller solutions (SConES and heinz). The consensus subnetwork captures mechanisms and genes known to be related to cancer, recovering known breast cancer susceptibility genes as well as genome regions associated to breast cancer susceptibility. However, thanks to its smaller size and its network structure, it provides compelling hypotheses of non-canonical mechanisms involved in carcinogenesis, like mitochondrial translation and chaperone activity.

The strength of network-based analyses comes from leveraging prior knowledge to boost discovery. In consequence, they show their shortcomings in front of understudied genes, especially those not in the network. Out of the 32 767 genes that we can map the genotyped SNPs to, 60.7% (19 887) are not in the protein-protein interaction network. The majority of those (14 660) are non-coding genes, mainly lncRNA, miRNA, and snRNA (Supplementary Figure 6). The importance of these genes, like *CASC16*, is highlighted in Section 3.1. Among the excluded protein-coding genes we find genes like *NEK10* ($P\text{-value } 1.6 \times 10^{-5}$, located near *SLC4A7*) or *POU5F1B*, both linked to breast cancer susceptibility [1]. However, on average protein-coding

genes absent from the PPIN are less associated with this phenotype (Wilcoxon rank-sum P-value = 2.79×10^{-8} , median P-values of 0.43 and 0.47). As we are using interactions from high-throughput experiments, such difference cannot be due to well-known genes having more known interactions. As disease genes tend to be more central [37], we hypothesize that it is due to interactions between central genes being more likely. It is worth noting that network approaches that do not use PPIs, like SConES GS and GM, did recover SNPs in *NEK10* and *CASC16*. Lastly, all the methods rely heavily on how SNPs are mapped to genes. In Section 3.1 we highlight ambiguities that appear when genes overlap or are in linkage disequilibrium.

As not all databases compile the same interactions, the choice of the PPIN determines the final output. In this work we used exclusively interactions from HINT from high-throughput experiments. This responds to concerns of some authors about biases introduced by adding interactions coming from targeted studies in the literature [12, 16] where a “rich getting richer” phenomenon is observed: popular genes have a higher proportion of their interactions described. On the other hand, Huang et al. [24] found that the best predictor of the performance of a network for disease gene discovery is the size of the network. This also supports using the largest amount of interactions. To clarify their impact on this study, we compared the impact of using only physical interactions from high-throughput experiment versus interactions from both high-throughput and the literature (Section 2.3.4). We conclude that for most of the methods a larger network did not greatly impact the size or the stability of the solution, the classification accuracy, or the runtime (Supplementary Figure 7).

In order to produce the consensus network, we had to face the different interfaces, preprocessing steps, and unexpected behaviors of the various methods. To facilitate that other authors apply them to new datasets and aggregate their solutions, we built six nextflow pipelines [17] with a consistent interface and, whenever possible, parallelized computation. They are available on GitHub: <https://github.com/hclimente/gwas-tools>. Importantly, those methods that had a permissive license were compiled into a Docker image for easier use, which is available on Docker Hub [hclimente/gwas-tools](https://hub.docker.com/r/hclimente/gwas-tools).

Funding and acknowledgments

This project was supported by funding from Agence Nationale de la Recherche (ANR-18-CE45-0021-01). H.C-G. was funded by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie [666003]. Financial support for GENESIS resource and genotyping was provided by the Ligue Nationale contre le Cancer (grants PRE05/DSL, PRE07/DSL, PRE11/NA), the French National Institute of Cancer (INCa grant No b2008-029/LL-LC) and the comprehensive cancer center SiRIC, (Site de Recherche Intégrée sur le Cancer: Grant INCa-DGOS-4654).

GENESIS (GENE SISTers) is a French national study promoted by UNICANCER (Sinilnikova et al. BMC Cancer 2016). We wish to thank the genetic epidemiology platform (the PIGE, Plateforme d’Investigation en Génétique et Epidemiologie : Séverine Eon-Marchais, M. Marcou, D. Le Gal, L. Toulemonde, J. Beauvallet, N. Mebirouk, E. Cavaciuti), the biological resource centre (S. Mazoyer, F. Damiola, L. Barjhoux, C. Verny-Pierre, V. Sornin) and all the GENESIS collaborating cancer clinics (Clinique Sainte Catherine, Avignon: H. Dreyfus; Hôpital Saint Jacques, Besançon: M-A. Collonge-Rame; Institut Bergonié, Bordeaux: M.Longy, A. Floquet, E. Barouk-Simonet; CHU, Brest: S. Audebert; Centre François Baclesse, Caen: P. Berthet; Hôpital Dieu, Chambéry: S. Fert-Ferrer; Centre Jean Perrin, Clermont-Ferrand: Y-J. Bignon; Hôpital Pasteur, Colmar: J-M. Limacher; Hôpital d’Enfants CHU – Centre Georges François Leclerc, Dijon: L. Faivre-Olivier; CHU, Fort de France: O. Bera; CHU Albert Michallon, Grenoble: D. Leroux; Hôpital Flaubert, Le Havre: V. Layet; Centre Oscar Lambret, Lille: P. Vennin†, C. Adenis; Hôpital Jeanne de Flandre, Lille: S. Lejeune-Dumoulin, S. Manouvrier-Hanu; CHRU Dupuytren, Limoges: L. Venat-Bouvet;

Centre Léon Bérard, Lyon: C. Lasset, V. Bonadona; Hôpital Edouard Herriot, Lyon: S. Giraud; Institut Paoli-Calmettes, Marseille: F. Eisinger, L. Huiart; Centre Val d'Aurelle – Paul Lamarque, Montpellier: I. Coupier; CHU Arnaud de Villeneuve, Montpellier: I. Coupier, P. Pujol; Centre René Gauducheau, Nantes: C. Delnatte; Centre Catherine de Sienne, Nantes: A. Lortholary; Centre Antoine Lacassagne, Nice: M. Frénay, V. Mari; Hôpital Caremeau, Nîmes: J. Chiesa; Réseau Oncogénétique Poitou Charente, Niort: P. Gesta; Institut Curie, Paris: D. Stoppa-Lyonnet, M. Gauthier-Villars, B. Buecher, A. de Pauw, C. Abadie, M. Belotti; Hôpital Saint-Louis, Paris: O. Cohen-Haguenauer; Centre Viggo-Petersen, Paris: F. Cornélis; Hôpital Tenon, Paris: A. Fajac; GH Pitié Salpêtrière et Hôpital Beaujon, Paris: C. Colas, F. Soubrier, P. Hammel, A. Fajac; Institut Jean Godinot, Reims: C. Penet, T. D. Nguyen; Polyclinique Courlancy, Reims: L. Demange†, C. Penet; Centre Eugène Marquis, Rennes: C. Dugast; Centre Henri Becquerel, Rouen: A. Chevrier, T. Frebourg, J. Tinat, I. Tennevet, A. Rossi; Hôpital René Huguenin/Institut Curie, Saint Cloud: C. Noguès, L. Demange†, E. Mouret-Fourme; CHU, Saint-Etienne: F. Prieur; Centre Paul Strauss, Strasbourg: J-P. Fricker, H. Schuster; Hôpital Civil, Strasbourg: O. Caron, C. Maugard; Institut Claudius Regaud, Toulouse: L. Gladieff, V. Feillel; Hôpital Bretonneau, Tours: I. Mortemousque; Centre Alexis Vautrin, Vandoeuvre-les-Nancy: E. Luporsi; Hôpital de Bravois, Vandoeuvre-les-Nancy: P. Jonveaux; Gustave Roussy, Villejuif: A. Chompret†, O. Caron).

References

- [1] Shahana Ahmed, Gilles Thomas, Maya Ghoussaini, Catherine S Healey, Manjeet K Humphreys, Radka Platte, Jonathan Morrison, Melanie Maranian, Karen A Pooley, Robert Luben, Diana Eccles, D Gareth Evans, Olivia Fletcher, Nichola Johnson, Isabel dos Santos Silva, Julian Peto, Michael R Stratton, Nazneen Rahman, Kevin Jacobs, Ross Prentice, Garnet L Anderson, Aleksandar Rajkovic, J David Curb, Regina G Ziegler, Christine D Berg, Sandra S Buys, Catherine A McCarty, Heather Spencer Feigelson, Eugenia E Calle, Michael J Thun, W Ryan Diver, Stig Bojesen, Børge G Nordestgaard, Henrik Flyger, Thilo Dörk, Peter Schürmann, Peter Hillemanns, Johann H Karstens, Natalia V Bogdanova, Natalia N Antonenkova, Iosif V Zalutsky, Marina Bermisheva, Sardana Fedorova, Elza Khushnutdinova, Daehee Kang, Keun-Young Yoo, Dong Young Noh, Sei-Hyun Ahn, Peter Devilee, Christi J van Asperen, R A E M Tollenaar, Caroline Seynaeve, Montserrat Garcia-Closas, Jolanta Lissowska, Louise Brinton, Beata Peplonska, Heli Nevanlinna, Tuomas Heikkinen, Kristiina Aittomäki, Carl Blomqvist, John L Hopper, Melissa C Southey, Letitia Smith, Amanda B Spurdle, Marjanka K Schmidt, Annegien Broeks, Richard R van Hien, Sten Cornelissen, Roger L Milne, Gloria Ribas, Anna González-Neira, Javier Benitez, Rita K Schmutzler, Barbara Burwinkel, Claus R Bartram, Alfons Meindl, Hiltrud Brauch, Christina Justenhoven, Ute Hamann, Jenny Chang-Claude, Rebecca Hein, Shan Wang-Gohrke, Annika Lindblom, Sara Margolin, Arto Mannermaa, Veli-Matti Kosma, Vesa Kataja, Janet E Olson, Xianshu Wang, Zachary Fredericksen, Graham G Giles, Gianluca Severi, Laura Baglietto, Dallas R English, Susan E Hankinson, David G Cox, Peter Kraft, Lars J Vatten, Kristian Hveem, Merethe Kumle, Alice Sigurdson, Michele Doody, Parveen Bhatti, Bruce H Alexander, Maartje J Hooning, Ans M W van den Ouweland, Rogier A Oldenburg, Mieke Schutte, Per Hall, Kamila Czene, Jianjun Liu, Yuqing Li, Angela Cox, Graeme Elliott, Ian Brock, Malcolm W R Reed, Chen-Yang Shen, Jyh-Cherng Yu, Giu-Cheng Hsu, Shou-Tung Chen, Hoda Anton-Culver, Argyrios Ziogas, Irene L Andrulis, Julia A Knight, Jonathan Beesley, Ellen L Goode, Fergus Couch, Georgia Chenevix-Trench, Robert N Hoover, Bruce A J Ponder, David J Hunter, Paul D P Pharoah, Alison M Dunning, Stephen J Chanock, and Douglas F Easton. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nature*

- Genetics*, 41(5):585–590, May 2009. ISSN 1061-4036, 1546-1718. doi: 10.1038/ng.354. URL <http://www.nature.com/articles/ng.354>. 00000.
- [2] Chloé-Agathe Azencott. Network-Guided Biomarker Discovery. In *Machine Learning for Health Informatics*, volume 9605, pages 319–336. Springer International Publishing, Cham, 2016. ISBN 978-3-319-50477-3 978-3-319-50478-0. doi: 10.1007/978-3-319-50478-0_16. URL http://link.springer.com/10.1007/978-3-319-50478-0_16. 00000.
 - [3] Chloé-Agathe Azencott, Dominik Grimm, Mahito Sugiyama, Yoshinobu Kawahara, and Karsten M. Borgwardt. Efficient network-guided multi-locus association mapping with graph cuts. *Bioinformatics*, 29(13):i171–i179, July 2013. ISSN 1367-4803, 1460-2059. doi: 10.1093/bioinformatics/btt238. URL <https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btt238>. 00047.
 - [4] Albert-László Barabási, Natali Gulbahce, and Joseph Loscalzo. Network medicine: a network-based approach to human disease. *Nature Reviews Genetics*, 12(1):56–68, January 2011. ISSN 1471-0056, 1471-0064. doi: 10.1038/nrg2918. URL <http://www.nature.com/articles/nrg2918>. 02826.
 - [5] N.H. Barton, A.M. Etheridge, and A. Véber. The infinitesimal model: Definition, derivation, and implications. *Theoretical Population Biology*, 118:50–73, December 2017. ISSN 00405809. doi: 10.1016/j.tpb.2017.06.001. URL <https://linkinghub.elsevier.com/retrieve/pii/S0040580917300886>. 00054.
 - [6] D. Beisser, G. W. Klau, T. Dandekar, T. Muller, and M. T. Dittrich. BioNet: an R-Package for the functional analysis of biological networks. *Bioinformatics*, 26(8):1129–1130, April 2010. ISSN 1367-4803, 1460-2059. doi: 10.1093/bioinformatics/btq089. URL <https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btq089>. 00188.
 - [7] Evan A. Boyle, Yang I. Li, and Jonathan K. Pritchard. An Expanded View of Complex Traits: From Polygenic to Omnigenic. *Cell*, 169(7):1177–1186, June 2017. ISSN 00928674. doi: 10.1016/j.cell.2017.05.038. URL <https://linkinghub.elsevier.com/retrieve/pii/S0092867417306293>. 00586.
 - [8] Joan P. Breyer, Daniel C. Dorset, Travis A. Clark, Kevin M. Bradley, Tiina A. Wahlfors, Kate M. McReynolds, William H. Maynard, Sam S. Chang, Michael S. Cookson, Joseph A. Smith, Johanna Schleutker, William D. Dupont, and Jeffrey R. Smith. An Expressed Retrogene of the Master Embryonic Stem Cell Gene *POU5f1* Is Associated with Prostate Cancer Susceptibility. *The American Journal of Human Genetics*, 94(3):395–404, March 2014. ISSN 00029297. doi: 10.1016/j.ajhg.2014.01.019. URL <https://linkinghub.elsevier.com/retrieve/pii/S0002929714000573>. 00018.
 - [9] Abra G Brisbin, Yan W Asmann, Honglin Song, Ya-Yu Tsai, Jeremiah A Aakre, Ping Yang, Robert B Jenkins, Paul Pharoah, Fredrick Schumacher, David V Conti, David J Duggan, Mark Jenkins, John Hopper, Steven Gallinger, Polly Newcomb, Graham Casey, Thomas A Sellers, and Brooke L Fridley. Meta-analysis of 8q24 for seven cancers reveals a locus between *NOV* and *ENPP2* associated with cancer development. *BMC Medical Genetics*, 12(1):156, December 2011. ISSN 1471-2350. doi: 10.1186/1471-2350-12-156. URL <http://bmcmедgenet.biomedcentral.com/articles/10.1186/1471-2350-12-156>. 00033.
 - [10] Annalisa Buniello, Jacqueline A L MacArthur, Maria Cerezo, Laura W Harris, James Hayhurst, Cinzia Malangone, Aoife McMahon, Joannella Morales, Edward Mountjoy, Elliot Sollis, Daniel Suveges, Olga Vrousou, Patricia L Whetzel, Ridwan Amode, Jose A Guillen, Harpreet S Riat, Stephen J

- Trevanion, Peggy Hall, Heather Junkins, Paul Flicek, Tony Burdett, Lucia A Hindorff, Fiona Cunningham, and Helen Parkinson. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Research*, 47(D1): D1005–D1012, January 2019. ISSN 0305-1048, 1362-4962. doi: 10.1093/nar/gky1120. URL <https://academic.oup.com/nar/article/47/D1/D1005/5184712>. 00092.
- [11] William S. Bush and Jason H. Moore. Chapter 11: Genome-Wide Association Studies. *PLoS Computational Biology*, 8(12):e1002822, December 2012. ISSN 1553-7358. doi: 10.1371/journal.pcbi.1002822. URL <https://dx.plos.org/10.1371/journal.pcbi.1002822>. 00001.
 - [12] James J. Cai, Elhanan Borenstein, and Dmitri A. Petrov. Broker Genes in Human Disease. *Genome Biology and Evolution*, 2:815–825, January 2010. ISSN 1759-6653. doi: 10.1093/gbe/evq064. URL <https://academic.oup.com/gbe/article/doi/10.1093/gbe/evq064/581094>. 00060.
 - [13] Stuart K. Calderwood and Jianlin Gong. Heat Shock Proteins Promote Cancer: It’s a Protection Racket. *Trends in Biochemical Sciences*, 41(4):311–323, April 2016. ISSN 09680004. doi: 10.1016/j.tibs.2016.01.003. URL <https://linkinghub.elsevier.com/retrieve/pii/S0968000416000189>. 00105.
 - [14] Christopher C Chang, Carson C Chow, Laurent CAM Tellier, Shashaank Vattikuti, Shaun M Purcell, and James J Lee. Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience*, 4(1):7, December 2015. ISSN 2047-217X. doi: 10.1186/s13742-015-0047-8. URL <https://academic.oup.com/gigasience/article-lookup/doi/10.1186/s13742-015-0047-8>. 01610.
 - [15] Héctor Climente-González and Chloé-Agathe Azencott. martini. <https://www.bioconductor.org/packages/martini/>, 2019. Accessed: 2019-07-16.
 - [16] Jishnu Das and Haiyuan Yu. HINT: High-quality protein interactomes and their applications in understanding human disease. *BMC Systems Biology*, 6(1):92, 2012. ISSN 1752-0509. doi: 10.1186/1752-0509-6-92. URL <http://bmcsystbiol.biomedcentral.com/articles/10.1186/1752-0509-6-92>. 00204.
 - [17] Paolo Di Tommaso, Maria Chatzou, Evan W Floden, Pablo Prieto Barja, Emilio Palumbo, and Cedric Notredame. Nextflow enables reproducible computational workflows. *Nature Biotechnology*, 35(4):316–319, April 2017. ISSN 1087-0156, 1546-1696. doi: 10.1038/nbt.3820. URL <http://www.nature.com/articles/nbt.3820>. 00176.
 - [18] M. T. Dittrich, G. W. Klau, A. Rosenwald, T. Dandekar, and T. Muller. Identifying functional modules in protein-protein interaction networks: an integrated exact approach. *Bioinformatics*, 24(13):i223–i231, July 2008. ISSN 1367-4803, 1460-2059. doi: 10.1093/bioinformatics/btn161. URL <https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btn161>. 00429.
 - [19] Marcus Dittrich and Daniela Beisser. Bionet. <https://bioconductor.org/packages/BioNet/>, 2008. Accessed: 2019-07-16.
 - [20] Adam Frankish, Mark Diekhans, Anne-Maud Ferreira, Rory Johnson, Irwin Jungreis, Jane Loveland, Jonathan M Mudge, Cristina Sisú, James Wright, Joel Armstrong, If Barnes, Andrew Berry, Alexandra Bignell, Silvia Carbonell Sala, Jacqueline Chrast, Fiona Cunningham, Tomás Di Domenico, Sarah Donaldson, Ian T Fiddes, Carlos García Giron, Jose Manuel Gonzalez, Tiago Grego, Matthew Hardy, Thibaut Hourlier, Toby Hunt, Osagie G Izuogu, Julien Lagarde, Fergal J Martin, Laura Martínez,

- Shamika Mohanan, Paul Muir, Fabio C P Navarro, Anne Parker, Baikang Pei, Fernando Pozo, Magali Ruffier, Bianca M Schmitt, Eloise Stapleton, Marie-Marthe Suner, Irina Sycheva, Barbara Uszczynska-Ratajczak, Jinuri Xu, Andrew Yates, Daniel Zerbino, Yan Zhang, Bronwen Aken, Jyoti S Choudhary, Mark Gerstein, Roderic Guigó, Tim J P Hubbard, Manolis Kellis, Benedict Paten, Alexandre Reymond, Michael L Tress, and Paul Flicek. GENCODE reference annotation for the human and mouse genomes. *Nucleic Acids Research*, 47(D1):D766–D773, January 2019. ISSN 0305-1048, 1362-4962. doi: 10.1093/nar/gky955. URL <https://academic.oup.com/nar/article/47/D1/D766/5144133>. 00063.
- [21] Laura I. Furlong. Human diseases through the lens of network biology. *Trends in Genetics*, 29(3): 150–159, March 2013. ISSN 01689525. doi: 10.1016/j.tig.2012.11.004. URL <https://linkinghub.elsevier.com/retrieve/pii/S0168952512001886>. 00128.
- [22] Frederik Gwinner. Leanr. <https://cran.r-project.org/web/packages/LEANR/>, 2016. Accessed: 2019-07-16.
- [23] Frederik Gwinner, Gwénola Boulday, Claire Vandiedonck, Minh Arnould, Cécile Cardoso, Iryna Nikolayeva, Oriol Guitart-Pla, Cécile V. Denis, Olivier D. Christophe, Johann Beghain, Elisabeth Tournier-Lasserre, and Benno Schwikowski. Network-based analysis of omics data: The LEAN method. *Bioinformatics*, page btw676, October 2016. ISSN 1367-4803, 1460-2059. doi: 10.1093/bioinformatics/btw676. URL <https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btw676>. 00007.
- [24] Justin K. Huang, Daniel E. Carlin, Michael Ku Yu, Wei Zhang, Jason F. Kreisberg, Pablo Tamayo, and Trey Ideker. Systematic Evaluation of Molecular Networks for Discovery of Disease Genes. *Cell Systems*, 6(4):484–495.e5, April 2018. ISSN 24054712. doi: 10.1016/j.cels.2018.03.001. URL <https://linkinghub.elsevier.com/retrieve/pii/S2405471218300954>. 00024.
- [25] Peilin Jia, Siyuan Zheng, Jirong Long, Wei Zheng, and Zhongming Zhao. dmGWAS: dense module searching for genome-wide association studies in protein-protein interaction networks. *Bioinformatics*, 27(1):95–102, January 2011. ISSN 1460-2059, 1367-4803. doi: 10.1093/bioinformatics/btq615. URL <https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btq615>. 00205.
- [26] Mark D M Leiserson, Fabio Vandin, Hsin-Ta Wu, Jason R Dobson, Jonathan V Eldridge, Jacob L Thomas, Alexandra Papoutsaki, Younhun Kim, Beifang Niu, Michael McLellan, Michael S Lawrence, Abel Gonzalez-Perez, David Tamborero, Yuwei Cheng, Gregory A Ryslik, Nuria Lopez-Bigas, Gad Getz, Li Ding, and Benjamin J Raphael. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. *Nature Genetics*, 47(2):106–114, February 2015. ISSN 1061-4036, 1546-1718. doi: 10.1038/ng.3168. URL <http://www.nature.com/articles/ng.3168>. 00411.
- [27] Mark D M Leiserson, Fabio Vandin, Hsin-Ta Wu, Jason R Dobson, Jonathan V Eldridge, Jacob L Thomas, Alexandra Papoutsaki, Younhun Kim, Beifang Niu, Michael McLellan, Michael S Lawrence, Abel Gonzalez-Perez, David Tamborero, Yuwei Cheng, Gregory A Ryslik, Nuria Lopez-Bigas, Gad Getz, Li Ding, and Benjamin J Raphael. Hotnet2. <https://github.com/raphael-group/hotnet2>, 2018. Accessed: 2019-07-16.
- [28] Guohong Liu, Francois X. Claret, Fuling Zhou, and Yunbao Pan. Jab1/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer. *Frontiers in*

- Pharmacology*, 9:135, February 2018. ISSN 1663-9812. doi: 10.3389/fphar.2018.00135. URL <http://journal.frontiersin.org/article/10.3389/fphar.2018.00135/full>. 00005.
- [29] Yuanlong Liu. Sigmod v2. <https://github.com/YuanlongLiu/SigMod>, 2018. Accessed: 2019-07-16.
- [30] Yuanlong Liu, Myriam Brossard, Damian Roqueiro, Patricia Margaritte-Jeannin, Chloé Sarnowski, Emmanuelle Bouzigon, and Florence Demenais. SigMod: an exact and efficient method to identify a strongly interconnected disease-associated module in a gene network. *Bioinformatics*, page btx004, January 2017. ISSN 1367-4803, 1460-2059. doi: 10.1093/bioinformatics/btx004. URL <https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btx004>. 00007.
- [31] Ivana Ljubić, René Weiskircher, Ulrich Pfersch, Gunnar W. Klau, Petra Mutzel, and Matteo Fischetti. An Algorithmic Framework for the Exact Solution of the Prize-Collecting Steiner Tree Problem. *Mathematical Programming*, 105(2-3):427–449, February 2006. ISSN 0025-5610, 1436-4646. doi: 10.1007/s10107-005-0660-x. URL <http://link.springer.com/10.1007/s10107-005-0660-x>. 00223.
- [32] Kyriaki Michailidou, Jonathan Beesley, Sara Lindstrom, Sander Canisius, Joe Dennis, Michael J Lush, Mel J Maranian, Manjeet K Bolla, Qin Wang, Mitul Shah, Barbara J Perkins, Kamila Czene, Mikael Eriksson, Hatf Darabi, Judith S Brand, Stig E Bojesen, Børge G Nordestgaard, Henrik Flyger, Sune F Nielsen, Nazneen Rahman, Clare Turnbull, Olivia Fletcher, Julian Peto, Lorna Gibson, Isabel dos Santos-Silva, Jenny Chang-Claude, Dieter Flesch-Janys, Anja Rudolph, Ursula Eilber, Sabine Behrens, Heli Nevanlinna, Taru A Muranen, Kristiina Aittomäki, Carl Blomqvist, Sofia Khan, Kirsimari Aaltonen, Habibul Ahsan, Muhammad G Kibriya, Alice S Whittemore, Esther M John, Kathleen E Malone, Marilie D Gammon, Regina M Santella, Giske Ursin, Enes Makalic, Daniel F Schmidt, Graham Casey, David J Hunter, Susan M Gapstur, Mia M Gaudet, W Ryan Diver, Christopher A Haiman, Fredrick Schumacher, Brian E Henderson, Loic Le Marchand, Christine D Berg, Stephen J Chanock, Jonine Figueroa, Robert N Hoover, Diether Lambrechts, Patrick Neven, Hans Wildiers, Erik van Limbergen, Marjanka K Schmidt, Annegien Broeks, Senno Verhoef, Sten Cornelissen, Fergus J Couch, Janet E Olson, Emily Hallberg, Celine Vachon, Quinten Waisfisz, Hanne Meijers-Heijboer, Muriel A Adank, Rob B van der Luijt, Jingmei Li, Jianjun Liu, Keith Humphreys, Daehee Kang, Ji-Yeob Choi, Sue K Park, Keun-Young Yoo, Keitaro Matsuo, Hidemi Ito, Hiroji Iwata, Kazuo Tajima, Pascal Guénel, Thérèse Truong, Claire Mulot, Marie Sanchez, Barbara Burwinkel, Frederik Marme, Harald Surowy, Christof Sohn, Anna H Wu, Chiu-chen Tseng, David Van Den Berg, Daniel O Stram, Anna González-Neira, Javier Benitez, M Pilar Zamora, Jose Ignacio Arias Perez, Xiao-Ou Shu, Wei Lu, Yu-Tang Gao, Hui Cai, Angela Cox, Simon S Cross, Malcolm W R Reed, Irene L Andrulis, Julia A Knight, Gord Glendon, Anna Marie Mulligan, Elinor J Sawyer, Ian Tomlinson, Michael J Kerin, Nicola Miller, Annika Lindblom, Sara Margolin, Soo Hwang Teo, Cheng Har Yip, Nur Aishah Mohd Taib, Gie-Hooi Tan, Maartje J Hoening, Antoinette Hollestelle, John W M Martens, J Margriet Collée, William Blot, Lisa B Signorello, Qiuyin Cai, John L Hopper, Melissa C Southey, Helen Tsimiklis, Carmel Apicella, Chen-Yang Shen, Chia-Ni Hsiung, Pei-Ei Wu, Ming-Feng Hou, Vessela N Kristensen, Silje Nord, Grethe I Grenaker Alnaes, Graham G Giles, Roger L Milne, Catriona McLean, Federico Canzian, Dimitrios Trichopoulos, Petra Peeters, Eiliv Lund, Malin Sund, Kay-Tee Khaw, Marc J Gunter, Domenico Palli, Lotte Maxild Mortensen, Laure Dossus, Jose-Maria Huerta, Alfons Meindl, Rita K Schmutzler, Christian Sutter, Rongxi Yang, Kenneth Muir, Artitaya Lophatananon, Sarah Stewart-Brown, Pornthep Siriwanarangsarn, Mikael Hartman, Hui Miao, Kee Seng Chia, Ching Wan Chan, Peter A Fasching, Alexander Hein, Matthias W Beckmann, Lothar Haeberle, Hermann Brenner, Aida Karina Dieffenbach, Volker Arndt, Christa Stegmaier, Alan Ashworth, Nick Orr, Minouk J Schoemaker, Anthony J Swerdlow, Louise Brinton, Montserrat Garcia-Closas, Wei Zheng, Sandra L Halverson, Martha

- Shrubsole, Jirong Long, Mark S Goldberg, France Labrèche, Martine Dumont, Robert Winqvist, Katri Pylkäs, Arja Jukkola-Vuorinen, Mervi Grip, Hiltrud Brauch, Ute Hamann, Thomas Brüning, Paolo Radice, Paolo Peterlongo, Siranoush Manoukian, Loris Bernard, Natalia V Bogdanova, Thilo Dörk, Arto Mannermaa, Vesa Kataja, Veli-Matti Kosma, Jaana M Hartikainen, Peter Devilee, Robert A E M Tollenaar, Caroline Seynaeve, Christi J Van Asperen, Anna Jakubowska, Jan Lubinski, Katarzyna Jaworska, Tomasz Huzarski, Suleeporn Sangrajang, Valerie Gaborieau, Paul Brennan, James McKay, Susan Slager, Amanda E Toland, Christine B Ambrosone, Drakoulis Yannoukakos, Maria Kabisch, Diana Torres, Susan L Neuhausen, Hoda Anton-Culver, Craig Luccarini, Caroline Baynes, Shahana Ahmed, Catherine S Healey, Daniel C Tessier, Daniel Vincent, Francois Bacot, Guillermo Pita, M Rosario Alonso, Nuria Álvarez, Daniel Herrero, Jacques Simard, Paul P D P Pharoah, Peter Kraft, Alison M Dunning, Georgia Chenevix-Trench, Per Hall, and Douglas F Easton. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nature Genetics*, 47(4):373–380, April 2015. ISSN 1061-4036, 1546-1718. doi: 10.1038/ng.3242. URL <http://www.nature.com/articles/ng.3242>. 00000.
- [33] Aniket Mishra and Stuart Macgregor. VEGAS2: Software for More Flexible Gene-Based Testing. *Twin Research and Human Genetics*, 18(1):86–91, February 2015. ISSN 1832-4274, 1839-2628. doi: 10.1017/thg.2014.79. URL https://www.cambridge.org/core/product/identifier/S1832427414000796/type/journal_article. 00125.
- [34] P. Nakka, B. J. Raphael, and S. Ramachandran. Gene and Network Analysis of Common Variants Reveals Novel Associations in Multiple Complex Diseases. *Genetics*, 204(2):783–798, October 2016. ISSN 0016-6731. doi: 10.1534/genetics.116.188391. URL <http://www.genetics.org/cgi/doi/10.1534/genetics.116.188391>. 00015.
- [35] Iryna Nikolayeva, Oriol Guitart Pla, and Benno Schwikowski. Network module identification—A widespread theoretical bias and best practices. *Methods*, 132:19–25, January 2018. ISSN 10462023. doi: 10.1016/j.ymeth.2017.08.008. URL <https://linkinghub.elsevier.com/retrieve/pii/S1046202317300373>.
- [36] Sarah Nogueira and Gavin Brown. Measuring the Stability of Feature Selection. In *Machine Learning and Knowledge Discovery in Databases*, volume 9852, pages 442–457. Springer International Publishing, Cham, 2016. ISBN 978-3-319-46226-4 978-3-319-46227-1. doi: 10.1007/978-3-319-46227-1_28. URL http://link.springer.com/10.1007/978-3-319-46227-1_28. 00000.
- [37] Janet Piñero, Ariel Berenstein, Abel Gonzalez-Perez, Ariel Chernomoretz, and Laura I. Furlong. Uncovering disease mechanisms through network biology in the era of Next Generation Sequencing. *Scientific Reports*, 6(1):24570, April 2016. ISSN 2045-2322. doi: 10.1038/srep24570. URL <http://www.nature.com/articles/srep24570>. 00016.
- [38] Janet Piñero, Àlex Bravo, Núria Queralt-Rosinach, Alba Gutiérrez-Sacristán, Jordi Deu-Pons, Emilio Centeno, Javier García-García, Ferran Sanz, and Laura I. Furlong. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. *Nucleic Acids Research*, 45(D1):D833–D839, January 2017. ISSN 0305-1048, 1362-4962. doi: 10.1093/nar/gkw943. URL <https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkw943>. 00369.
- [39] David A. Quigley, Elisa Fiorito, Silje Nord, Peter Van Loo, Grethe Grenaker Alnaes, Thomas Fleischer, Jorg Tost, Hans Kristian Moen Vollan, Trine Tramm, Jens Overgaard, Ida R. Bukholm, Antoni Hurtado,

- Allan Balmain, Anne-Lise Børresen-Dale, and Vessela Kristensen. The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors. *Molecular Oncology*, 8(2):273–284, March 2014. ISSN 15747891. doi: 10.1016/j.molonc.2013.11.008. URL <http://doi.wiley.com/10.1016/j.molonc.2013.11.008>. 00000.
- [40] Erica S. Rinella, Yongzhao Shao, Lauren Yackowski, Sreemanta Pramanik, Ruth Oratz, Freya Schnabel, Saurav Guha, Charles LeDuc, Christopher L. Campbell, Susan D. Klugman, Mary Beth Terry, Ruby T. Senie, Irene L. Andrulis, Mary Daly, Esther M. John, Daniel Roses, Wendy K. Chung, and Harry Ostrer. Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. *Human Genetics*, 132(5):523–536, May 2013. ISSN 0340-6717, 1432-1203. doi: 10.1007/s00439-013-1269-4. URL <http://link.springer.com/10.1007/s00439-013-1269-4>. 00019.
- [41] Lori C Sakoda, Eric Jorgenson, and John S Witte. Turning of COGS moves forward findings for hormonally mediated cancers. *Nature Genetics*, 45(4):345–348, April 2013. ISSN 1061-4036, 1546-1718. doi: 10.1038/ng.2587. URL <http://www.nature.com/articles/ng.2587>. 00060.
- [42] S. Scheid and R. Spang. twilight; a Bioconductor package for estimating the local false discovery rate. *Bioinformatics*, 21(12):2921–2922, June 2005. ISSN 1367-4803, 1460-2059. doi: 10.1093/bioinformatics/bti436. URL <https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/bti436>. 00054.
- [43] SEARCH, The GENICA Consortium, kConFab, Australian Ovarian Cancer Study Group, Shahana Ahmed, Gilles Thomas, Maya Ghoussaini, Catherine S Healey, Manjeet K Humphreys, Radka Platte, Jonathan Morrison, Melanie Maranian, Karen A Pooley, Robert Luben, Diana Eccles, D Gareth Evans, Olivia Fletcher, Nichola Johnson, Isabel dos Santos Silva, Julian Peto, Michael R Stratton, Nazneen Rahman, Kevin Jacobs, Ross Prentice, Garnet L Anderson, Aleksandar Rajkovic, J David Curb, Regina G Ziegler, Christine D Berg, Sandra S Buys, Catherine A McCarty, Heather Spencer Feigelson, Eugenia E Calle, Michael J Thun, W Ryan Diver, Stig Bojesen, Børge G Nordestgaard, Henrik Flyger, Thilo Dörk, Peter Schürmann, Peter Hillemanns, Johann H Karstens, Natalia V Bogdanova, Natalia N Antonenkova, Iosif V Zalutsky, Marina Bermisheva, Sardana Fedorova, Elza Khusnutdinova, Daehee Kang, Keun-Young Yoo, Dong Young Noh, Sei-Hyun Ahn, Peter Devilee, Christi J van Asperen, R A E M Tollenaar, Caroline Seynaeve, Montserrat Garcia-Closas, Jolanta Lissowska, Louise Brinton, Beata Peplonska, Heli Nevanlinna, Tuomas Heikkinen, Kristiina Aittomäki, Carl Blomqvist, John L Hopper, Melissa C Southey, Letitia Smith, Amanda B Spurdle, Marjanka K Schmidt, Annegien Broeks, Richard R van Hien, Sten Cornelissen, Roger L Milne, Gloria Ribas, Anna González-Neira, Javier Benitez, Rita K Schmutzler, Barbara Burwinkel, Claus R Bartram, Alfons Meindl, Hiltrud Brauch, Christina Justenhoven, Ute Hamann, Jenny Chang-Claude, Rebecca Hein, Shan Wang-Gohrke, Annika Lindblom, Sara Margolin, Arto Mannermaa, Veli-Matti Kosma, Vesa Kataja, Janet E Olson, Xianshu Wang, Zachary Fredericksen, Graham G Giles, Gianluca Severi, Laura Baglietto, Dallas R English, Susan E Hankinson, David G Cox, Peter Kraft, Lars J Vatten, Kristian Hveem, Merethe Kumle, Alice Sigurdson, Michele Doody, Parveen Bhatti, Bruce H Alexander, Maartje J Hooning, Ans M W van den Ouweland, Rogier A Oldenburg, Mieke Schutte, Per Hall, Kamila Czene, Jianjun Liu, Yuqing Li, Angela Cox, Graeme Elliott, Ian Brock, Malcolm W R Reed, Chen-Yang Shen, Jyh-Cherng Yu, Giu-Cheng Hsu, Shou-Tung Chen, Hoda Anton-Culver, Argyrios Ziogas, Irene L Andrulis, Julia A Knight, Jonathan Beesley, Ellen L Goode, Fergus Couch, Georgia Chenevix-Trench, Robert N Hoover, Bruce A J Ponder, David J Hunter, Paul D P Pharoah, Alison M Dunning, Stephen J Chanock,

- and Douglas F Easton. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nature Genetics*, 41(5):585–590, May 2009. ISSN 1061-4036, 1546-1718. doi: 10.1038/ng.354. URL <http://www.nature.com/articles/ng.354>. 00000.
- [44] Olga M. Sinilnikova, Marie-Gabrielle Dondon, Séverine Eon-Marchais, Francesca Damiola, Laure Barjhoux, Morgane Marcou, Carole Verny-Pierre, Valérie Sornin, Lucie Toulemonde, Juana Beauvallet, Dorothée Le Gal, Noura Mebirouk, Muriel Belotti, Olivier Caron, Marion Gauthier-Villars, Isabelle Coupier, Bruno Buecher, Alain Lortholary, Catherine Dugast, Paul Gesta, Jean-Pierre Fricker, Catherine Noguès, Laurence Faivre, Elisabeth Luporsi, Pascaline Berthet, Capucine Delnatte, Valérie Bonadona, Christine M. Maugard, Pascal Pujol, Christine Lasset, Michel Longy, Yves-Jean Bignon, Claude Adenis, Laurence Venat-Bouvet, Liliane Demange, Hélène Dreyfus, Marc Frenay, Laurence Gladieff, Isabelle Mortemousque, Séverine Audebert-Bellanger, Florent Soubrier, Sophie Giraud, Sophie Lejeune-Dumoulin, Annie Chevrier, Jean-Marc Limacher, Jean Chiesa, Anne Fajac, Anne Floquet, François Eisinger, Julie Tinat, Chrystelle Colas, Sandra Fert-Ferrer, Clotilde Penet, Thierry Frebourg, Marie-Agnès Collonge-Rame, Emmanuelle Barouk-Simonet, Valérie Layet, Dominique Leroux, Odile Cohen-Haguenauer, Fabienne Prieur, Emmanuelle Mouret-Fourme, François Cornélis, Philippe Jonveaux, Odile Bera, Eve Cavaciuti, Anne Tardivon, Fabienne Lesueur, Sylvie Mazoyer, Dominique Stoppa-Lyonnet, and Nadine Andrieu. GENESIS: a French national resource to study the missing heritability of breast cancer. *BMC Cancer*, 16(1):13, December 2016. ISSN 1471-2407. doi: 10.1186/s12885-015-2028-9. URL <http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-2028-9>. 00005.
- [45] Peter M. Visscher, Naomi R. Wray, Qian Zhang, Pamela Sklar, Mark I. McCarthy, Matthew A. Brown, and Jian Yang. 10 Years of GWAS Discovery: Biology, Function, and Translation. *The American Journal of Human Genetics*, 101(1):5–22, July 2017. ISSN 00029297. doi: 10.1016/j.ajhg.2017.06.005. URL <https://linkinghub.elsevier.com/retrieve/pii/S0002929717302409>. 00634.
- [46] Maggie Haitian Wang, Heather J. Cordell, and Kristel Van Steen. Statistical methods for genome-wide association studies. *Seminars in Cancer Biology*, May 2018. ISSN 1044579X. doi: 10.1016/j.semcancer.2018.04.008. URL <https://linkinghub.elsevier.com/retrieve/pii/S1044579X1730278X>. 00001.
- [47] Quan Wang and Peilin Jia. dmGWAS 3.0. <https://bioinfo.uth.edu/dmGWAS/>, 2014. Accessed: 2019-07-16.

Supplementary materials

Table 1: Summary statistics on the results of SConES on the three SNP-SNP interaction networks. The first row within each block contains the summary statistics on the whole network.

Network	SNPs	Edges	Subnetworks	$\overline{\text{Betweenness}}$	\hat{P}_{SNP}
GS	197 083	197 060	-	2.03×10^7	0.49
SConES GS	1 590	1 585	5	2.52×10^7	0.023
GM	197 083	6 442 446	-	3.99×10^6	0.49
SConES GM	1 692	177 611	5	4.40×10^6	0.055
GI	197 083	28 733 720	-	1.46×10^6	0.49
SConES GI	408	539	5	9.33×10^6	0.076

$\overline{\text{Betweenness}}$: mean betweenness of the selected SNPs in the corresponding full network; \hat{P}_{SNP} : median P-value of the selected SNPs.

Table 2: Summary statistics on the results of multiple network methods on the gene-gene interaction network. The first row contains the summary statistics on the whole network.

Network	Genes	Edges	$\overline{\text{Betweenness}}$	\hat{P}_{gene}	$\rho_{\text{consensus}}$
SConES GS	5	0	9 805	2.7×10^{-5}	0.19
SConES GM	28	2	4 267	0.067	0.12

$\overline{\text{Betweenness}}$: mean betweenness of the selected genes in the full network; \hat{P}_{gene} : median P-value of the selected genes; $\rho_{\text{consensus}}$: Pearson's correlation with the consensus network.




Fig. 1: GENESIS shows no differential population structure between cases and controls. (A,B,C,D) Eight main principal components computed on the genotypes of GENESIS. Cases are colored in green, controls in orange.




Fig. 2: Association in GENESIS. The red line represents the Bonferroni threshold. **(A)** SNP association, measured from the outcome of a 1 d.f. χ^2 allelic test. Significant SNPs that are within a coding gene, or within 50 kilobases²⁹ of its boundaries, are annotated. The Bonferroni threshold is 2.54×10^{-7} . **(B)** Gene association, measured by P-value of VEGAS2v2 [33] using the 10% of SNPs with the lowest P-values. The Bonferroni threshold is 1.53×10^{-6} . **(C)** SNP association as in panel (A). The SNPs in black are selected by a L1-penalized logistic regression (Section 2.4.1, $\lambda = 0.03$).





Fig. 3: Pearson's correlation between the different solution subnetworks. **(A)** Correlation between selected SNPs. **(B)** Correlation between selected genes. In general, the solutions display a very low overlap.

A



B




Fig. 4: Consensus subnetwork on GENESIS (Section 2.3.3). **(A)** Each node is represented by a pie chart, which shows the methods that selected it. The labeled genes have a VEGAS2v2 P-value < 0.001 and/or are known breast cancer susceptibility genes (colored in pink). This panel is identical to Figure 2. **(B)** Manhattan plot showing the genes included in the subnetwork. **(C)** Every gene name is indicated. **(D,E)** Proportion of the Bonferroni significant genes (in GENESIS and BCAC, respectively) included in the consensus network. **F** Proportion of the selected genes by each of the methods on the GENESIS data that is a known breast cancer susceptibility gene, as in Figure 1D




Fig. 5: Genes on the consensus network. Breast cancer susceptibility genes are colored in pink; the rest are colored in grey. **(A)** Number of methods selecting every gene in the subnetwork. **(B)** VEGAS P-values of association of the genes, with regards to the number of methods that selected them. **(C)** Comparison of betweenness centrality of the genes in the consensus network and the other genes in the PPIN and not in the consensus network. To improve visualization, we removed outliers. **(D)** Relationship between the \log_{10} of the betweenness centrality and the $-\log_{10}$ of the VEGAS P-value of the genes in the consensus network. The blue line represents a fitted generalized linear model.




Fig. 6: Biotypes of genes from the annotation that are not present in the HINT protein-protein interaction network.




Fig. 7: Comparison of benchmark on high-throughput interactions to benchmark on both high-throughput and literature curated interactions. Grey lines represent no change between the benchmarks (1 for ratios, 0 for differences). **(A)** Ratios of the selected features between both benchmarks and of the active set. **(B)** Shifts in sensitivity and specificity. **(C)** Shift in Pearson's correlation between benchmarks. **(D)** Ratio between the runtimes of the benchmarks. For gene network-based methods, inverted triangles represent the ratio of runtimes of the algorithms themselves, and circles the total time, which includes the algorithm themselves and the additional 119980 seconds (1 day and 9.33 hours) which took VEGAS2v2 on average to compute the gene scores from SNP summary statistics. In general, adding additional interactions slightly improves the stability of the solution, but increases the solution size, has mixed effects on the sensitivity and specificity, and impacts negatively the required runtime of the algorithms.




Fig. 8: TODO.